Dr Thompson has been working together with Prof Louise Emmett and colleagues, in partnership with Clarity Pharmaceuticals, to develop and open the PROPELLOR trial of Cu64 PSMA PET vs conventional Ga68 PSMA PET CT for staging prostate cancer in men with intermediate to high risk prostate cancer, prior to robotic radical prostatectomy.
It has previously been established that Gallium (Ga68) PSMA has less than ideal accuracy for tiny spots of prostate cancer that have spread to lymph nodes and bones. The multicentre trial will assess whether the new Copper (Cu64) ligand has a higher accuracy (sensitivity and specificity) than Ga68 for detecting tiny spots of prostate cancer that have spread beyond the prostate.
The trial is now open and Dr Thompson has just enrolled the first study participant.